Form 4: Syndax Pharmaceuticals Director Katkin Acquires 10,000 Shares
SEC Form 4 Filing
Director Keith Katkin purchased 10,000 shares of Syndax Pharmaceuticals at $9.112 per share on May 19, 2025.
Summary
- On May 19, 2025, Keith Katkin, a director of Syndax Pharmaceuticals Inc., acquired 10,000 shares of common stock.
- The purchase price was $9.112 per share.
- Following the transaction, Katkin directly owns 100,000 shares of Syndax Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It reflects a standard transaction by a company director. The purchase could be interpreted as a positive signal, but without further context, it's difficult to gauge the overall impact.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders of a company (officers, directors, or any individuals owning more than 10% of the company's shares) buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The purchase of shares by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of transaction: Keith Katkin purchased 10,000 shares of Syndax Pharmaceuticals. |
| 05/19/2025 | Date of report: Michael A. Metzger signed the report as Attorney-in-Fact. |
Keywords
Syndax Pharmaceuticals, SNDX, Katkin, Director, Stock Purchase, Form 4, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.